Donanemab
Alzheimer's Disease
Phase 3Regulatory Review
Key Facts
About Eli Lilly
Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |
| NVG-291 | NervGen Pharma | Phase 1b/2a |